Cytosorbents (NASDAQ:CTSO) Stock Passes Above Two Hundred Day Moving Average of $0.93

Cytosorbents Co. (NASDAQ:CTSO)’s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.93 and traded as high as $1.08. Cytosorbents shares last traded at $1.08, with a volume of 149,912 shares traded.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on CTSO. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a report on Tuesday, May 7th. StockNews.com started coverage on shares of Cytosorbents in a report on Saturday. They set a “hold” rating for the company. Finally, B. Riley reissued a “buy” rating and issued a $3.00 price objective on shares of Cytosorbents in a research note on Wednesday, May 15th.

Cytosorbents Stock Performance

The firm has a market cap of $58.65 million, a P/E ratio of -1.83 and a beta of 0.57. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.21 and a current ratio of 1.49. The company’s 50 day moving average is $0.87 and its 200 day moving average is $0.93.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). The business had revenue of $9.79 million during the quarter, compared to the consensus estimate of $9.78 million. Cytosorbents had a negative net margin of 75.07% and a negative return on equity of 129.89%. During the same quarter in the prior year, the firm earned ($0.17) EPS. As a group, equities analysts predict that Cytosorbents Co. will post -0.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cytosorbents

Large investors have recently modified their holdings of the business. Key Client Fiduciary Advisors LLC raised its stake in shares of Cytosorbents by 188.0% during the first quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 22,557 shares during the last quarter. Raymond James & Associates bought a new position in shares of Cytosorbents during the fourth quarter valued at $56,000. CM Management LLC raised its stake in shares of Cytosorbents by 98.8% during the first quarter. CM Management LLC now owns 825,000 shares of the medical research company’s stock valued at $784,000 after acquiring an additional 410,000 shares during the last quarter. Sargent Investment Group LLC raised its stake in shares of Cytosorbents by 4.1% during the fourth quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock valued at $1,453,000 after acquiring an additional 51,699 shares during the last quarter. Finally, Neuberger Berman Group LLC raised its stake in shares of Cytosorbents by 19.9% during the fourth quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock valued at $1,997,000 after acquiring an additional 299,103 shares during the last quarter. Institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.